Newswise — TAMPA, Fla. – June 11, 2012 – Saneron CCEL Therapeutics, Inc. of Tampa, Florida, and South Texas Blood & Tissue Center of San Antonio, have signed a clinical supply and research collaboration agreement. Under the agreement, the South Texas Blood & Tissue Center will research approaches for recovering and processing proprietary mononuclear cells from umbilical cord blood. From that inventory, Saneron will use the cells for future clinical trials to study possible therapies for restoring brain tissue in patients suffering from Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), also known as “Lou Gehrig's disease,” and the effects of stroke.
STBTC will provide the cord blood cells through its GenCure affiliate, which focuses on providing cell and tissue services for regenerative medicine therapy and research. “The opportunity to collaborate with Saneron to support research into potential new life-enhancing therapies is particularly gratifying because there are currently so few restorative treatments available for patients with these devastating neurological disorders," said Mary Beth Fisk, MT, CTBS, CQA, president and COO of STBTC. “Partnering to support this type of regenerative medicine research - research that will have a huge impact on health care in the future - is the reason we established GenCure.”
According to Nicole Kuzmin-Nichols, MBA, Saneron president and COO, having access to a readily available supply of clinical grade U-CORD-CELL™, Saneron’s proprietary processed mononuclear cell fraction of cord blood, is crucial.
“We, too, are very pleased to partner with the South Texas Blood & Tissue Center to provide clinical grade umbilical cord blood for potential future neurological applications,” said Kuzmin-Nichols. As we move towards clinical trials, having access to a readily available supply of clinical grade U-CORD-CELL™, Saneron’s proprietary processed mononuclear cell fraction of cord blood, is crucial. We feel that STBTC has the both the expertise and volume of samples needed to be a key partner.”
About Saneron CCEL Therapeutics, Inc.Saneron CCEL Therapeutics, Inc. is a biotechnology R&D company focused on neurological and cardiac cell therapy for the early intervention and treatment of several devastating or deadly diseases which lack adequate treatment options. Saneron, a University of South Florida spin-out company, is located at the Tampa Bay Technology Incubator. Saneron is committed to providing readily available, noncontroversial stem cells for cellular therapies and has patented and patent-pending technology relating to its platform technology of umbilical cord blood and Sertoli cells.
About South Texas Blood & Tissue CenterThe South Texas Blood & Tissue Center (STBTC) is a not-for profit community blood center specializing in a variety of services. Blood Services provides blood, plasma, platelets and other blood components to over 100 hospitals and clinics in 43 South Texas counties. STBTC has seven donor rooms in South Texas and conducts multiple mobile blood drives each week. GenCure, which focuses on regenerative medicine, includes Tissue Services, the National Marrow Donor Program and the Texas Cord Blood Bank. QualTex Laboratories provides specialized testing for blood and source plasma products.
For further information please contact:Saneron CCEL Therapeutics Inc.,Nicole Kuzmin-Nichols, MBA3802 Spectrum Blvd., Suite 112FTampa, FL 33612Phone: email@example.com South Texas Blood & Tissue CenterCarmen Davila6211 IH 10 West San Antonio, TX 78201Phone: firstname.lastname@example.org
Forward-Looking Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.